Outcome Measures: |
Primary: Subjects With Adverse Events as a Measure of Safety and Tolerability, The objective of the current study was to investigate the safety and preliminary efficacy of doses up to 200 mg 5-ALA - SFC in a population of patients with type 2 diabetes mellitus living in Bahrain., Week 2, Week 4, Week 12|Change From Baseline in Fasting Blood Glucose, The objective of the current study was to investigate the safety and preliminary efficacy of doses up to 200 mg 5-ALA - SFC in a population of patients with type 2 diabetes mellitus living in Bahrain., Baseline, Week 2, Week 4, Week 12 | Secondary: Change From Baseline in 2 Hour Post Meal Glucose Level, Change from baseline in blood glucose levels 2 hours after breakfast, Baseline, Week 2, Week 4, Week 12|Change From Baseline in Body Weight, Change from baseline measured at week 6 and week 12 only, Baseline, Week 6, Week 12|Change From Baseline in HbA1c, Change from baseline in HbA1c %, Baseline, Week 2, Week 4, Week 12|Change From Baseline in Total Cholesterol (Component of Lipid Profile), Change from baseline measured at week 6 and week 12 only, Baseline, Week 6, Week 12|Change From Baseline LDL (Component of Lipid Profile), Change from baseline measured at week 6 and week 12 only, Baseline, Week 6, Week 12|Change From Baseline in HDL (Component of Lipid Profile), Change from baseline measured at week 6 and week 12 only, Baseline, Week 6, Week 12|Change From Baseline in Triglycerides (Component of Lipid Profile), Change from baseline measured at week 6 and week 12 only, Baseline, Week 6, Week 12
|